

Massimo Bertinaria obtained his MD in pharmaceutical chemistry and technologies at the University of Turin (Italy) in 1993. He completed his education obtaining a MD in pharmacy at the same Institution.

As a post-graduate scientist, he specialized in heterocyclic chemistry at the University of East Anglia (UK) under the supervision of Prof. A McKillop and AJ Boulton. Later on, he joined the PhD program in medicinal chemistry at the University of Turin and received his PhD in February 1999. In the same year he was appointed assistant professor in medicinal chemistry at the Department of Drug Science and Technology, University of Turin, and in 2011 he took over the role of associate professor at the same University.

In 2013, he established the SynBioMed research group. SynBioMed research is focused on the design and synthesis of new chemical entities and multi-target drugs acting on inflammatory signaling. At present SynBioMed is actively developing NLRP3 inflammasome inhibitors and dual TP receptor antagonists/COX-2 inhibitors.